{"entity":{"id":"nct06747585","kind":"trial","name":"A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of ALE.P02 in non-small-cell lung cancer, head and neck squamous cell carcinoma and oesophageal cancer, run by Alentis Therapeutics AG, now recruiting.","summary":"A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors is a phase 1/2 interventional study registered as NCT06747585 by Alentis Therapeutics AG, with 170 participants planned, started 2024-12-16 and due to reach its primary completion in 2028-02-15. Interventions recorded: ALE.P02.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06747585","url":"https://clinicaltrials.gov/study/NCT06747585"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc","head-and-neck","esophageal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["alentis-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06747585","phase":"1/2","setting":"A Phase I/II, Open-Label, Multicenter Study of ALE.P02 (Claudin-1 Targeted Antibody-Drug Conjugate) as a Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+Squamous Solid Tumors","sponsor":"Alentis Therapeutics AG","enrolled":170,"outcomes":[]},"route":"/trials/nct06747585/","neighbours":{"cancer":[{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"esophageal","kind":"cancer","name":"Oesophageal cancer","route":"/cancers/esophageal/"}],"company":[{"id":"alentis-therapeutics","kind":"company","name":"Alentis Therapeutics","route":"/companies/alentis-therapeutics/"}]}}